A novel nanoparticle system using platelet membrane fragments to deliver liraglutide significantly inhibited diabetes-induced atherosclerosis in laboratory and animal studies.
85.56% encapsulation efficiencyThe nanoparticles captured most of the liraglutide loaded into them and released it steadily over 24 hours, while effectively targeting atherosclerotic damage.
What the researchers found
The BSA@LIR-PMF nanoparticles achieved a drug loading rate of 7.96% and encapsulation efficiency of 85.56%, with approximately 77% cumulative drug release over 24 hours. The nanoparticles were spherical, uniform in size, and maintained stable platelet membrane protein structure.
In functional testing, the nanoparticles effectively inhibited abnormal cell proliferation and migration triggered by oxidized LDL (ox-LDL), reduced reactive oxygen species (ROS) levels and lactate concentrations, and enhanced ATP levels by improving oxidative phosphorylation. In animal models, BSA@LIR-PMF significantly inhibited diabetes-induced atherosclerosis and reduced lipid deposition in the aortas.
Why it matters
Liraglutide requires daily injections, which can be burdensome for patients managing chronic conditions. A targeted nanoparticle delivery system could improve drug efficacy while reducing injection frequency. The platelet membrane coating is particularly clever because platelets naturally home to sites of vascular injury — potentially delivering liraglutide directly where atherosclerotic damage is occurring.
How the study worked
Researchers prepared nanoparticles by encapsulating liraglutide in bovine serum albumin (BSA) and coating them with platelet membrane fragments (PMF). They characterized the nanoparticles for size, shape, stability, and membrane protein integrity. Effectiveness was tested both in vitro (using ox-LDL-stimulated cells to model atherosclerosis) and in vivo (using diabetic mouse models), measuring cell proliferation, migration, phagocytosis, ROS, metabolic markers, and aortic lipid deposition.
What this study cannot tell us
This is a preclinical study using cell cultures and animal models — results may not directly translate to humans. The study used bovine serum albumin as the carrier protein, which would need to be replaced with human albumin for clinical use. Long-term safety of repeated nanoparticle administration and potential immune responses to platelet membrane fragments were not assessed. The diabetic atherosclerosis animal model may not fully capture the complexity of human disease.
How to read the evidence
This is a preclinical study combining in vitro cell experiments and in vivo animal models. While the results are promising, the evidence is preliminary — no human data exists for this delivery system. The study provides proof-of-concept but is far from clinical application.
When this study was published
Published in 2024, this is a very recent study representing current advances in peptide nanoparticle drug delivery research.
The bigger picture
Cardiovascular disease is the leading cause of death in people with diabetes, and atherosclerosis is a key driver. While GLP-1 receptor agonists like liraglutide have shown cardiovascular benefits in clinical trials, optimizing their delivery to vascular tissue could amplify these effects. This work sits at the intersection of peptide therapeutics and nanomedicine, a rapidly growing field that aims to make existing drugs work smarter through targeted delivery.
Questions still open
- How would this nanoparticle system perform in larger animal models or early human trials, and what would the dosing schedule look like?
- Could the platelet membrane targeting approach be adapted for other peptide drugs beyond liraglutide?
- What immune responses might occur with repeated administration of platelet membrane-coated nanoparticles?
Common questions
Why use platelet membrane fragments to deliver liraglutide?
Could this technology reduce the number of liraglutide injections patients need?
Read the original research
Preparation and characterization of BSA-loaded liraglutide and platelet fragment nanoparticle delivery system for the treatment of diabetic atherosclerosis.
Journal of nanobiotechnology, 22(1), 506
Citation
He, Mingping; Fang, Ming; Fan, Limin; Maimaitijiang, Alimujiang. (2024). Preparation and characterization of BSA-loaded liraglutide and platelet fragment nanoparticle delivery system for the treatment of diabetic atherosclerosis.. Journal of nanobiotechnology, 22(1), 506. https://doi.org/10.1186/s12951-024-02775-z